OverviewSuggest Edit

ChromaDex Corporation discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards; and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

TypePublic
Founded1999
HQIrvine, CA, US
Websitechromadex.com
Employee Ratings3.1
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)110(+10%)
Revenue (FY, 2020)$59.3 M(+29%)
Share Price (Sept 2021)$6.7
Cybersecurity ratingAMore

Key People/Management at ChromaDex

Robert Fried

Robert Fried

Chief Executive Officer, Director
Brianna Gerber

Brianna Gerber

Vice President of Finance and Investor Relations
Stephen A. Block

Stephen A. Block

Non-Executive Director
Alex Worsham

Alex Worsham

Vice President, Global Marketing & Communications
Jeffery Baxter

Jeffery Baxter

Non-Executive Director
Kurt Gustafson

Kurt Gustafson

Non-Executive Director
Show more

ChromaDex Office Locations

ChromaDex has offices in Irvine, Longmont, Los Angeles and Rockville
Irvine, CA, US (HQ)
10005 Muirlands Blvd
Longmont, CO, US
1751 S Fordham St #350
Los Angeles, CA, US
11150 Santa Monica Blvd Suite 600
Rockville, MD, US
11821 Parklawn Dr #310
Show all (4)

ChromaDex Financials and Metrics

ChromaDex Revenue

Embed Graph
View revenue for all periods
ChromaDex's revenue was reported to be $59.26 m in FY, 2020
USD

Revenue (Q1, 2021)

14.7m

Gross profit (Q1, 2021)

9.2m

Gross profit margin (Q1, 2021), %

62.9%

Net income (Q1, 2021)

(7.4m)

EBIT (Q1, 2021)

(7.4m)

Market capitalization (23-Sept-2021)

452.8m

Closing stock price (23-Sept-2021)

6.7

Cash (31-Mar-2021)

44.7m

EV

409.6m
ChromaDex's current market capitalization is $452.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

8.1m11.6m10.2m15.3m22.0m26.8m21.2m31.6m46.3m59.3m

Revenue growth, %

51%44%22%

Cost of goods sold

5.6m9.3m7.0m10.0m13.5m14.9m10.7m15.5m20.5m24.0m

Gross profit

2.5m2.3m3.1m5.3m8.5m11.9m10.5m16.1m25.8m35.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.9m1.8m1.8m2.7m3.6m2.3m2.7m2.7m3.1m3.9m4.1m6.3m5.3m6.1m7.3m8.8m5.0m4.4m5.3m6.1m1.2m7.8m8.1m10.0m11.1m12.1m14.3m15.3m14.2m14.7m

Cost of goods sold

1.4m1.4m2.4m1.9m2.4m1.7m1.7m2.0m2.1m2.5m2.6m3.8m3.3m3.6m3.9m4.7m3.0m2.7m3.0m3.2m3.4m4.0m3.8m4.7m4.8m5.3m6.0m6.2m5.7m5.4m

Gross profit

580.9k466.5k(604.2k)764.7k1.3m672.8k960.7k750.2k985.0k1.4m1.5m2.5m1.9m2.5m3.5m4.1m2.0m1.8m2.3m2.9m(2.2m)3.8m4.4m5.3m6.3m6.7m8.3m9.1m8.5m9.2m

Gross profit Margin, %

30%26%(34%)29%35%29%35%28%32%36%37%39%37%40%47%47%41%39%43%48%(186%)49%54%53%56%56%58%59%60%63%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

420.2k520.0k2.3m4.0m5.5m1.6m45.4m22.6m18.8m16.7m

Accounts Receivable

723.7k1.9m838.8k5.3m4.4m2.2m900.0k

Prepaid Expenses

903.9k261.3k271.4k655.3k577.0k996.0k1.1m

Inventories

2.9m5.2m2.2m3.7m8.2m7.9m5.8m8.2m11.5m11.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

2.0m2.1m5.8m2.2m1.2m966.6k826.6k1.1m1.9m1.3m1.2m4.7m3.2m5.7m3.0m3.4m2.3m1.2m14.1m24.0m41.0m33.4m28.2m19.3m19.8m18.9m13.6m18.9m15.5m44.7m

Accounts Receivable

841.9k648.8k1.4m988.2k1.2m986.4k1.2m1.0m4.3m6.8m6.5m5.0m4.6m4.9m4.8m5.1m4.8m5.3m5.7m6.0m3.6m4.0m3.2m

Prepaid Expenses

673.3k613.7k371.9k522.8k393.0k453.2k436.5k347.0k359.6k465.7k401.9k420.3k864.9k724.4k909.0k627.0k593.0k721.0k706.0k1.1m701.0k584.0k1.0m1.1m

Inventories

2.0m2.5m4.1m5.3m5.4m1.6m1.9m2.2m2.5m2.9m2.3m4.2m3.2m3.1m6.7m4.5m6.3m8.9m7.8m6.6m5.1m6.5m7.1m8.7m10.7m9.8m11.3m12.3m11.0m12.8m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(7.9m)(11.7m)(4.4m)(5.4m)(2.8m)(2.9m)(11.4m)(33.3m)(32.1m)(19.9m)

Depreciation and Amortization

328.6k328.1k269.7k419.6k716.1k842.0k1.0m1.1m

Inventories

1.5m2.3m466.4k(1.5m)(4.4m)240.9k(2.2m)2.5m3.3m148.0k

Accounts Payable

1.7m1.2m(1.6m)2.2m2.8m(245.7k)(2.4m)5.8m78.0k(181.0k)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(3.0m)(5.4m)(4.4m)(8.4m)(10.0m)1.5m478.8k(3.7m)(1.8m)(1.7m)(659.7k)(3.7k)(1.0m)(1.3m)255.6k173.0k(781.4k)(1.9m)(4.7m)(2.6m)(8.4m)(16.5m)(25.1m)(8.3m)(16.1m)(23.3m)(5.9m)(9.6m)(13.8m)(7.4m)

Depreciation and Amortization

165.9k247.0k85.4k166.7k247.2k79.2k134.3k204.5k93.8k197.8k297.5k153.3k354.0k544.0k179.0k383.0k611.0k234.0k485.0k743.0k276.0k554.0k834.0k281.0k

Inventories

(551.5k)1.1m(1.1m)2.3m2.5m(164.3k)206.8k479.9k2.9m2.3m4.2m3.2m645.3k(1.5m)(3.6m)(1.8m)964.6k(179.4k)(1.4m)(733.0k)730.0k1.3m421.0k2.5m1.6m255.0k804.0k(504.0k)1.1m

Accounts Payable

842.4k791.9k816.2k1.2m588.7k(683.2k)(907.3k)(712.1k)2.8m2.3m3.6m2.6m(357.1k)(3.3m)(3.9m)(2.1m)1.8m(3.0m)(1.7m)2.1m3.0m5.2m206.0k(224.0k)(3.4m)(1.5m)154.0k(2.7m)2.2m
USDQ2, 2012

Financial Leverage

1.6 x
Show all financial metrics

ChromaDex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

ChromaDex Online and Social Media Presence

Embed Graph

ChromaDex Company Culture

  • Overall Culture

    A+

    96/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

ChromaDex News and Updates

ChromaDex stock jumps after its Tru Niagen to become available at Walmart

Shares of ChromaDex Corp. shot up 12.8% in premarket trading Monday, after the maker of healthy aging supplements said its Tru Niagen will become available in 3,800 Walmart Inc. stores in the U.S. ChromaDex said Tru Niagen is a form of vitamin B3 that helps elevate NAD+, to reduce the impact of ag…

ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020

LOS ANGELES, Feb. 25, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Tues., Mar. 10, 2020 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended Dec. 31, 2019. The financial results will be reported in a press release …

ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide

ChromaDex launches new research tools for the CBD industry with line of reference standards ChromaDex launches new research tools for the CBD industry with line of reference standards

ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Austra…

ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®

LOS ANGELES, Dec. 16, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen® (nicotinam…

ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide

Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners
Show more

ChromaDex Frequently Asked Questions

  • When was ChromaDex founded?

    ChromaDex was founded in 1999.

  • Who are ChromaDex key executives?

    ChromaDex's key executives are Robert Fried, Brianna Gerber and Stephen A. Block.

  • How many employees does ChromaDex have?

    ChromaDex has 110 employees.

  • What is ChromaDex revenue?

    Latest ChromaDex annual revenue is $59.3 m.

  • What is ChromaDex revenue per employee?

    Latest ChromaDex revenue per employee is $538.7 k.

  • Who are ChromaDex competitors?

    Competitors of ChromaDex include Business and Decision Life Sciences, Nexus Medical Consulting and ERT.

  • Where is ChromaDex headquarters?

    ChromaDex headquarters is located at 10005 Muirlands Blvd, Irvine.

  • Where are ChromaDex offices?

    ChromaDex has offices in Irvine, Longmont, Los Angeles and Rockville.

  • How many offices does ChromaDex have?

    ChromaDex has 4 offices.